Skip to main content
Article thumbnail
Location of Repository

An emerging role for escitalopram in the treatment of obsessive-compulsive disorder

By Dawson W Hedges and Fu Lye M Woon

Abstract

Obsessive-compulsive disorder (OCD) is a common and severe neuropsychiatric disorder treated by both behavioral and pharmacologic techniques. Despite the availability of treatments for OCD, including the selective serotonin reuptake inhibitors (SSRIs), many OCD patients have an inadequate response to current treatments. As such, additional approaches to the management of OCD are required. A potential but little studied treatment for OCD is the SSRI escitalopram. Escitalopram is the S-enantiomer of citalopram, the preparation containing both S and R enantiomers of citalopram. Not only is escitalopram the most selective of the SSRIs, it is also devoid of R-citalopram, which may interfere with the effects of the S enantiomer. Escitalopram appears to be effective in depression and several anxiety disorders, including social anxiety disorder and generalized anxiety disorder, conditions in which it also appears reasonably well tolerated. Enantiomeric specificity, high serotonin reuptake selectivity, comparatively good tolerability and favorable pharmacokinetics, and preliminary evidence of efficacy in OCD suggest a potential role for the use of escitalopram in the treatment of OCD. Nevertheless, additional work including evaluating the use of escitalopram with behavioral interventions and in long-term treatment of OCD is needed to clarify its overall role in managing OCD

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2655080
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). A 24 week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
    2. (1999). A 40-year follow-up of patients with obsessivecompulsive disorder.
    3. (1991). A controlled trial of lithium augmentation in fl uvoxamine-refractory obsessive-compulsive disorder:lack of effi cacy.
    4. (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry,
    5. (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev,
    6. (2006). A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drugnaive patients with obsessive-compulsive disorder.
    7. (2003). A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv,
    8. (2004). A somatoform variant of obsessive-compulsive disorder: a case report of OCD presenting with persistent vomiting.
    9. (2004). Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    10. (2006). Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: long-term follow-up results. Stereotact Funct Neurosurg,
    11. (2000). Biological therapies for obsessive-compulsive disorder.
    12. (1992). Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder.
    13. (1998). Effect of adjuvant pindolol on the antiobsessional response to fl uvoxamine: a double-blind, placebocontrolled study. Int Clin Psychopharmacol,
    14. (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder:a quantitative review.
    15. (2004). Effi cacy and tolerability of escitalopram in 12- and 24 week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety,
    16. (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol,
    17. (2001). Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
    18. (2007). Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fi xed-dose, 24 week study. Curr Med Res Opin,
    19. (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, fl exible-dose study. Depress Anxiety,
    20. (2005). Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother,
    21. (2005). Escitalopram in the treatment of social anxiety disorder:randomised, placebo-controlled, fl exible-dosage study.
    22. (2007). Escitalopram prevents relapse of obsessive-compulsive disorder.
    23. (2006). Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol,
    24. (2004). Escitalopram treatment of transvestic fetishism: a case report.
    25. (2003). Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl),
    26. (2006). Escitalopram:a review of its use in the management of anxiety disorders.
    27. (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    28. (2005). Issues in the pharmacological treatment of anxiety disorders. Australas Psychiatry,
    29. (1993). Limited therapeutic effect of addition of buspirone in fl uvoxamine-refractory obsessivecompulsive disorder.
    30. (2004). Long-term treatment of generalized anxiety disorder with escitalopram. Eur Psychiatry,
    31. (2002). Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.
    32. (2000). Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
    33. (2004). Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety,
    34. (2005). Quality of life in obsessive-compulsive disorder before and after treatment. Compr Psychiatry,
    35. (2003). R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety.
    36. (2004). R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter.
    37. (2006). Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    38. (2004). Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
    39. (2003). Single photon emission computed tomography imaging in obsessive-compulsive disorder and for stereotactic bilateral anterior cingulotomy.
    40. (2002). Stereoisomers in psychiatry: the case of escitalopram.
    41. (2003). Stereotactic cingulotomy.
    42. (2005). The case for the OCD spectrum.
    43. (1988). The epidemiology of obsessive-compulsive disorder in fi ve US communities. Arch Gen Psychiatry,
    44. (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.
    45. (2005). The role of venlafaxine in the treatment of obsessive-compulsive disorder.
    46. (2002). Treatment non-response in OCD: methodological issues and operational definitions.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.